Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway
about
Lys-63-specific deubiquitination of SDS3 by USP17 regulates HDAC activityA phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanomaAction mechanisms of histone deacetylase inhibitors in the treatment of hematological malignanciesCombating the epigenome: epigenetic drugs against non-Hodgkin's lymphomaQuantitative proteomic analysis of post-translational modifications of human histonesDrosophila histone deacetylase-3 controls imaginal disc size through suppression of apoptosisInhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphomaPanobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of functionHistone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets.Diagnostic exercise: sudden death in a mouse with experimentally induced acute myeloid leukemia.Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ ExpressionHistone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cellsInhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo.Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibitionInhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds.Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.Systematic analysis of time-series gene expression data on tumor cell-selective apoptotic responses to HDAC inhibitors.Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.Chemoresistance to Valproate Treatment of Bovine Leukemia Virus-Infected Sheep; Identification of Improved HDAC Inhibitors.TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt.Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNKEradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathwayRuvBL2 is involved in histone deacetylase inhibitor PCI-24781-induced cell death in SK-N-DZ neuroblastoma cells.Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitorRomidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphomaNovel Interaction of Class IIb Histone Deacetylase 6 (HDAC6) with Class IIa HDAC9 Controls Gonadotropin Releasing Hormone (GnRH) Neuronal Cell Survival and MovementAnalysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphomaDesign and Evaluation of Tumor-Specific Dendrimer Epigenetic Therapeutics.A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitorsHistone deacetylase inhibitors: insights into mechanisms of lethality.
P2860
Q24337169-EB27BCD5-7282-43CA-A422-CBA4EBCA9017Q24658533-26F43D6B-81C8-40D2-B2C1-1376049457C0Q26739689-7F5E5362-2E90-4661-8DBD-55ACF7A990EEQ26851166-C1E38B67-CD97-4E58-84D6-6362E3FD60BAQ28235630-84DAF908-1C73-4F74-ACF7-7F30A73E4E01Q28472324-B21F727B-0957-4DD7-BB86-2B2D8982E939Q28534761-CCD685C7-B819-4AD6-BBB2-2F5D8BA92E41Q28535006-A12AD79D-3246-4ACC-826A-977B9A4F22F9Q30459589-DE54FAA8-3A85-4991-9AC1-905933E274F7Q30873726-796889D6-12ED-4CB6-9A1F-7658D14A3444Q33224746-15F194AD-1E1B-4320-B2F2-8CD2A7E1EC99Q33255121-B9132B0C-C4CB-4F3C-82AB-28C8B0C07355Q33388188-E1F87C34-9C9F-42CB-84A9-0690376C2D90Q33482772-EB299199-C897-4AD1-B75C-3DA1B4236B74Q33755131-C8AF7506-63D2-4B50-9CE8-2E62E34CECCAQ33808800-96486BB8-50FB-47BB-B091-09DA97EE2E47Q33831971-C560ED0A-0C0E-40F9-BA6F-C9841B25599FQ33900608-09029BE6-9866-4261-B000-BDB61F1D008BQ33917016-7B8275DF-D343-403D-866F-F4FEB507C778Q34115920-C46AF7EA-8E38-4D18-9FF6-C04F913FBB1BQ34240470-AAD4C172-90CC-4D3F-AE62-540CAEEB1123Q34249695-203D0AC9-FA08-4F0C-8148-A05DD6E8C3B8Q34254302-95A02927-F8BA-420C-81D1-F5BC502E5AA8Q34399444-235F5E71-5D9E-4F1E-A21D-24769E5603C3Q34413200-DA0040F8-D1E8-46BF-BDB0-41B7220F83E8Q34416994-09724FBC-A356-47DE-8F1A-32671F873AFEQ34533413-35DA7AE0-3770-46B4-9493-F614C18AB7C0Q34564468-8BFD452D-ABE2-48EB-9378-86036DB65C2CQ34568521-8CDC7F4D-CC2E-429E-B0C4-6C01190E97EDQ34652570-0B00D5E9-828E-4F5D-9797-D77661419925Q34749665-0B6C5B70-EEE3-476B-BE64-81B23750808AQ34952741-331C740F-73BC-4385-A878-9CE113A55A3EQ34971840-955892C7-106A-45D1-93D8-DAD2C754E9B0Q35070323-2EBB9EA8-1A58-4FCB-808F-735ED464CDEFQ35186682-75A8D64C-19B1-4B24-A8E1-5BED0C177C22Q35662350-23E47D9E-3DFB-4EAB-8A82-52AD217FAC7FQ35808910-C91535C4-2803-4A37-8BD6-A4D4E3D287C8Q35908427-748194FC-22B2-4947-8BC9-1B450B859DA4Q36140582-256D2105-805F-422D-AE0E-75F9C06BCB33Q36219726-B397B348-D366-4924-B6C0-684F9C404D2C
P2860
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway
description
im Dezember 2004 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 26 December 2004
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2004
@uk
name
Inhibitors of histone deacetyl ...... of the death receptor pathway
@en
Inhibitors of histone deacetyl ...... of the death receptor pathway
@nl
type
label
Inhibitors of histone deacetyl ...... of the death receptor pathway
@en
Inhibitors of histone deacetyl ...... of the death receptor pathway
@nl
prefLabel
Inhibitors of histone deacetyl ...... of the death receptor pathway
@en
Inhibitors of histone deacetyl ...... of the death receptor pathway
@nl
P2093
P2860
P356
P1433
P1476
Inhibitors of histone deacetyl ...... of the death receptor pathway
@en
P2093
Alessandra Insinga
Andrea Viale
Francesco Marchesi
Pier Giuseppe Pelicci
Saverio Minucci
Silvia Monestiroli
Simona Ronzoni
Vania Gelmetti
P2860
P2888
P356
10.1038/NM1160
P407
P577
2004-12-26T00:00:00Z
P6179
1029661228